Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.66 |
| ▸ | CD74 | P04233 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18171805 | 0.84 | ALDH1A1 (0.50) | MIFCD74MAPTPOLBMEN1 | |
| SCHEMBL10874258 | 0.80 | MIF (1.00) | MIFCD74TP53POLBMEN1 | |
| SCHEMBL18805702 | 0.77 | MIF (1.00) | MIFCD74MAPTTP53POLB | |
| SCHEMBL17807837 | 0.77 | NPC1 (0.79) | MIFCD74MAPTTP53POLB | |
| SCHEMBL16554239 | 0.77 | MIF (0.70) | MIFCD74MAPTTP53POLB | |
| SCHEMBL18171842 | 0.77 | MIF (0.70) | MIFCD74MAPTTP53POLB | |
| SCHEMBL25124429 | 0.76 | IDH1 (0.52) | TP53POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL16565537 | 0.76 | MIF (0.76) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL244386 | 0.76 | MIF (1.00) | MIFCD74POLBMEN1KMT2A | |
| SCHEMBL29906983 | 0.76 | MIF (1.00) | MIFCD74POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| EP-3286174-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172425-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | MIF 349/4885CD74 576/4885MAPT 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.